| 2002 | Randomized, double-blind study on The Efficacy and Safety of Tigecycline for the Treatment of Complicated Intra-Abdominal Infections. Sponsor: Wyeth Research |
Phase III |
| 2008 | A Multinational, Multicenter, Randomized, Double Blind Study Comparing the Efficacy and Safety of AVE5026 With Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery Sponsor: Sanofi-Aventis |
Phase III |
| 2008 | A Phase 2 Double-Blind, Placebo Controlled, Multi-Center Adjuvant Trial of the Efficacy, Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant Saccharomyces Cerevisiae Expressing Mutant Ras Protein Combined With a Gemcitabine Regimen Versus a Gemcitabine Regimen With Placebo, in Patients With Post-Resection R0/R1 Pancreatic Cancer With Tumor Sequence Confirmation of Ras Mutations. Sponsor: Globeimmune |
Phase II |
| 2009 | Prospective Multicenter Doubleblind Randomized Study of NXL104/Ceftazidime + Metronidazole vs. Meropenem in Treatment of Complicated Intra-abdominal Infections Sponsor: Novexel Inc. |
Phase II |
| 2011 | Randomized, double-blind, double-dummy, multicenter, prospective study to Compare TP-434 and Ertapenem in CA Complicated Intra-abdominal Infections. Sponsor: Tetraphase Pharmaceuticals, Inc. |
Phase II |
